Balixafortide (Polyphor) is a synthetic cyclopeptide derived from polyphemusin that inhibits C-X-C motif chemokine receptor 4 (CXCR4), a G-protein coupled receptor that exclusively binds to its ligand, stromal cell-derived factor-1 (SDF-1). The CXCR4/SDF-1 axis stimulates cell migration, induces cell proliferation and angiogenesis, and promotes invasion in both cancer cells and cells of the immune system. CXCR4 antagonists block the interaction of CXCR4 and SDF-1, inhibiting cancer metastasis by limiting the migratory and invasive potential of the cancer cells.
Although normal breast cells do not express CXCR4, approximately 75% of triple-negative breast cancer patients have high levels of CXCR4 expression. Additionally, SDF-1 is selectively expressed in the lymph nodes, lungs, liver, and bone marrow, which are the most common sites of breast cancer metastasis.
4 Drug Overview
5 Product Profiles
5 balixafortide : Breast cancer: triple-negative
LIST OF FIGURES
10 Figure 1: Datamonitor Healthcare’s drug assessment summary of balixafortide for TNBC
10 Figure 2: Datamonitor Healthcare’s drug assessment summary of balixafortide for TNBC
LIST OF TABLES
6 Table 1: Balixafortide drug profile
8 Table 2: Late-phase trials of balixafortide for TNBC
9 Table 3: Balixafortide for TNBC – SWOT analysis
This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.